Newsletter

Archive

Relief Reports that its U.S. Collaboration Partner has announced that it has Submitted an Application to the FDA seeking Emergency Use Authorization for Aviptadil to Treat Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies

Relief Reports that its U.S. Collaboration Partner has announced that it has Submitted an Application to the FDA seeking Emergency Use Authorization for Aviptadil to Treat Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies

Geneva, Switzerland, January 6, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”), of its collaboration partner with respect to aviptadil, NeuroRx, Inc. ("NeuroRx") has announced that it has submitted an application to the FDA seeking emergency use authorization ("EUA") for the use of aviptadil to treat patients with critical COVID-19 who are at immediate risk of death from respiratory failure despite treatment with approved therapy including Remdesivir and who are ineligible for enrollment into the ACTIV-3b NIH-sponsored trial. The related NRx press release can be accessed through the following link.

Relief also updated the market on recent activities in its pending lawsuit against NeuroRx and NeuroRx's CEO, Jonathan Javitt (collectively, the "Defendants"), relating to the parties' collaboration agreement with respect to the development and commercialization of aviptadil. Relief reported that the Defendants have filed two motions with the Court: (i) a motion to dismiss seeking the dismissal of Jonathan Javitt from the case for lack of personal jurisdiction, or, in the alternative, on the merits, and (ii) a motion to strike certain statements made in Relief's complaint. Relief has begun its review of the defendants' filings and will respond at a future time in an appropriate filing with the Court. While there can be no assurance, Relief remains confident in the statements made in its complaint and in the validity of its claims against NeuroRx and Jonathan Javitt. Relief also reported that its previously announced mediation with the Defendants seeking to amicably resolve the litigation is currently scheduled for late February 2022.

ABOUT RELIEF

Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief’s lead drug candidate, RLF-100™ (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. In addition, Relief's recently completed acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH, bring to Relief a diverse pipeline of marketed and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY.  For more information, visit www.relieftherapeutics.com.  Follow us on LinkedIn.


Contact:

RELIEF THERAPEUTICS Holding SA

Jack Weinstein
Chief Financial Officer and Treasurer 
This email address is being protected from spambots. You need JavaScript enabled to view it.

For media inquiries contact:

Rx Communications Group

Michael Miller
Tel:+1-917-633-6086
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor relations contact:

Rx Communications Group

Michael Miller
Tel:+1-917-633-6086
This email address is being protected from spambots. You need JavaScript enabled to view it.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors, including (i) whether NeuroRx's recently submitted application to the FDA seeking for EUA for aviptadil to treat patients with critical COVID-19 who are at immediate risk of death from respiratory failure despite treatment with approved therapy including Remdesivir and who are ineligible for enrollment into the ACTIV-3b NIH-sponsored trial will be approved, (ii) whether RELIEF THERAPEUTICS Holding SA will be successful in its lawsuit against NRx's subsidiary, NeuroRx, and NeuroRx's CEO, Jonathan Javitt, (iii) whether the mediation will be successful, (iv) whether aviptadil will ever be approved in the U.S., the U.K., or the E.U. for the treatment of respiratory failure in patients with COVID-19 or any other disease, and (v) those risks discussed in RELIEF THERAPEUTICS Holding SA's press releases and filings with the SIX, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.